OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
IZO.CD59

Izotropic Corp

Advanced Medical Equipment & TechnologyVerified

Izotropic Corp has a highly leveraged capital structure, with total liabilities of CAD 4,078,630 and total equity of CAD -3,846,250, resulting in a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.04 and a debt-to-equity ratio of -0.53, indicating that liabilities significantly outweigh equity. Despite a small amount of cash and equivalents (CAD 28,750), the company's operating cash flow is negative at CAD -593,570, and free cash flow is only CAD 14,990, suggesting limited ability to fund operations or reduce debt. Profitability is severely constrained, with a net income of CAD 170 and an operating income of CAD 90,420. The return on assets is a minimal 0.07%, and return on equity is effectively zero, indicating that the company is not generating returns that justify its asset base or equity investment. These metrics fall well below the industry median for profitability and returns, which typically require higher margins and asset efficiency to sustain operations. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector, where demand can be sensitive to regulatory changes and technological shifts. Looking ahead, the company is expected to see a modest increase in revenue, with analyst estimates projecting CAD 5,000,000 for the current fiscal year. However, this represents a relatively small growth rate compared to historical performance, and the company's ability to meet these projections is constrained by its weak liquidity and high debt load. The operating cash flow remains a concern, as it is insufficient to cover debt obligations or support meaningful reinvestment. The company faces several risk factors, including liquidity constraints and the potential for dilution if it issues additional shares to raise capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net worth and high debt-to-equity ratio suggest that the company may need to seek additional financing in the near term. The risk of dilution is currently low, but the company's financial position could deteriorate if it is unable to improve its cash flow or secure new funding. Recent filings and transcripts indicate that the company is actively seeking to improve its financial position through cost-cutting measures and potential partnerships. However, no significant new product launches or major contracts have been disclosed in the latest available data. The company's management has acknowledged the need for strategic adjustments to address its liquidity challenges and improve long-term sustainability.

30-day price · IZO.CD+0.07 (+33.3%)
Low$0.21High$0.33Close$0.30As of17 May, 00:00 UTC
Profile
CompanyIzotropic Corp
TickerIZO.CD
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Izotropic Corp designs and sells advanced medical equipment, primarily focused on diagnostic and therapeutic devices for healthcare applications.

Classification. Izotropic Corp is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a classification confidence of 0.92.

Izotropic Corp has a highly leveraged capital structure, with total liabilities of CAD 4,078,630 and total equity of CAD -3,846,250, resulting in a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.04 and a debt-to-equity ratio of -0.53, indicating that liabilities significantly outweigh equity. Despite a small amount of cash and equivalents (CAD 28,750), the company's operating cash flow is negative at CAD -593,570, and free cash flow is only CAD 14,990, suggesting limited ability to fund operations or reduce debt. Profitability is severely constrained, with a net income of CAD 170 and an operating income of CAD 90,420. The return on assets is a minimal 0.07%, and return on equity is effectively zero, indicating that the company is not generating returns that justify its asset base or equity investment. These metrics fall well below the industry median for profitability and returns, which typically require higher margins and asset efficiency to sustain operations. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector, where demand can be sensitive to regulatory changes and technological shifts. Looking ahead, the company is expected to see a modest increase in revenue, with analyst estimates projecting CAD 5,000,000 for the current fiscal year. However, this represents a relatively small growth rate compared to historical performance, and the company's ability to meet these projections is constrained by its weak liquidity and high debt load. The operating cash flow remains a concern, as it is insufficient to cover debt obligations or support meaningful reinvestment. The company faces several risk factors, including liquidity constraints and the potential for dilution if it issues additional shares to raise capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net worth and high debt-to-equity ratio suggest that the company may need to seek additional financing in the near term. The risk of dilution is currently low, but the company's financial position could deteriorate if it is unable to improve its cash flow or secure new funding. Recent filings and transcripts indicate that the company is actively seeking to improve its financial position through cost-cutting measures and potential partnerships. However, no significant new product launches or major contracts have been disclosed in the latest available data. The company's management has acknowledged the need for strategic adjustments to address its liquidity challenges and improve long-term sustainability.
Key takeaways
  • Izotropic Corp has a highly leveraged capital structure with a negative net worth and weak liquidity.
  • The company's profitability is minimal, with a near-zero return on equity and a very low return on assets.
  • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • Analysts project modest revenue growth, but the company's ability to meet these targets is constrained by its financial position.
  • The company faces liquidity risks and may need to seek additional financing, which could lead to dilution.
  • Management is focused on cost-cutting and strategic adjustments to improve financial sustainability.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyCAD
Revenue
Gross profit
Operating income$90.4k
Net income$170.00
R&D
SG&A
D&A
SBC
Operating cash flow-$593.6k
CapEx$0.00
Free cash flow$15.0k
Total assets$232.4k
Total liabilities$4.1M
Total equity-$3.8M
Cash & equivalents$28.8k
Long-term debt$2.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$5.0M-$5.0M-$5.0M
FY-3-$6.7M-$6.7M-$6.7M
FY-2-$5.7M-$5.7M-$5.7M
FY-1-$1.3M-$1.6M-$1.5M
FY0-$2.8M-$3.1M-$3.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$4.7M$4.5M
FY-3$2.3M-$374.6k
FY-2$442.1k-$3.1M
FY-1$232.4k-$3.8M$28.8k
FY0$414.7k-$4.9M$0.00
PeriodOCFCapExFCFSBC
FY-4-$3.1M-$5.0M
FY-3-$4.8M-$24.2k-$6.7M
FY-2-$3.3M-$36.2k-$5.7M
FY-1-$593.6k$0.00-$1.5M
FY0-$636.2k-$1.1k-$3.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$90.4k$170.00$15.0k
FQ-6-$1.2M-$1.3M-$1.2M
FQ-5-$296.4k-$345.3k-$331.8k
FQ-4-$426.4k-$487.3k-$474.7k
FQ-3-$893.5k-$1.0M-$1.0M
FQ-2-$360.4k-$425.0k-$414.4k
FQ-1-$558.0k-$787.9k-$783.9k
FQ0-$426.7k-$262.1k-$254.5k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$232.4k-$3.8M$28.8k
FQ-6$282.6k-$4.3M$0.00
FQ-5$274.5k-$4.5M$0.00
FQ-4$382.1k-$4.8M$0.00
FQ-3$414.7k-$4.9M$0.00
FQ-2$209.0k-$5.2M$0.00
FQ-1$447.1k-$5.5M
FQ0$685.3k-$5.3M
PeriodOCFCapExFCFSBC
FQ-7-$593.6k$0.00$15.0k
FQ-6-$104.6k-$1.2M
FQ-5-$187.2k-$331.8k
FQ-4-$395.5k-$1.1k-$474.7k
FQ-3-$636.2k-$1.1k-$1.0M
FQ-2-$220.4k-$414.4k
FQ-1-$563.2k-$783.9k
FQ0-$720.4k$0.00-$254.5k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$3.8M
Net cash-$2.0M
Current ratio0.0
Debt/Equity-0.5
ROA0.1%
ROE-0.0%
Cash conversion-3491.6%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricIZO.CDActivity
Op margin-16.5% medp25 -174.5% · p75 8.8%
Net margin-16.5% medp25 -172.4% · p75 8.4%
Gross margin47.4% medp25 34.2% · p75 65.3%
CapEx / revenue-5.4% medp25 -12.5% · p75 -2.2%
Debt / equity-53.0%4.3% medp25 0.0% · p75 28.0%bottom quartile
Observations
IR observations
Mean price target0.82 CAD
Median price target0.82 CAD
High price target0.82 CAD
Low price target0.82 CAD
Mean EPS estimate0.03 CAD
Mean revenue estimate5,000,000 CAD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 00:06 UTC#365a93e3
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 06:24 UTCJob: 103217b4